Clinicopathological and functional significance of XRCC1 expression in ovarian cancer

Tarek M.A. Abdel-Fatah(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Rebeka Sultana(University of Nottingham), Stephen Chan(Heidelberg University), Rachel Abbotts(University of Nottingham), Claire Hawkes(University of Warwick), Claire Seedhouse(University of Nottingham)
International Journal of Cancer
December 6, 2012
10.1002/ijc.27980
Cited by 64

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374